Patent Assignment
Reel/Frame 024741/0060
Release of Security Interest
Recorded: 2010-07-26
Received: 2010-07-26
Pages: 9
Assignor
GOLDMAN SACHS CREDIT PARTNERS L.P., AS COLLATERAL AGENT
Executed: 2007-03-09
Assignee
RELIANT PHARMACEUTICALS, INC.
110 ALLEN ROAD, LIBERTY CORNER, NJ, 07938, UNITED STATES
Covered Properties
(28)
Treatment of fatty liver
Application:
11/649,881 →
System and Method for Manufacturing Oral Osmotic Drug Delivery Devices, and Methods of Administering Same
Application:
11/615,163 →
Treatment with dihydropyridine calcium channel blockers and omega-3 fatty acids and a combination product thereof
Application:
11/494,799 →
Treatment with azetidinone-based cholesterol absorption inhibitors and omega-3 fatty acids and a combination product thereof
Application:
11/488,181 →
Oral osmotic drug delivery system
Application:
11/432,670 →
Oral osmotic drug delivery system
Application:
11/432,661 →
Oral osmotic drug delivery system
Application:
11/432,671 →
Sustained release delivery of isradipine
Application:
11/377,648 →
Treatment with Statin and Omega-3 Fatty Acids and a Combination Product Thereof
Application:
11/370,178 →
Essential N-3 Fatty Acids in Cardiac Insufficiency and Heart Failure Therapy
Application:
11/333,387 →
Treatment with omega-3 fatty acids and PPAR agonist and/or antagonist and a combination product thereof
Application:
11/293,513 →
Stable compositions of fenofibrate with fatty acid esters
Application:
11/293,496 →
Oral osmotic drug delivery system
Application:
11/292,305 →
Omega-3 fatty acids and dyslipidemic agent for lipid therapy
Application:
11/284,095 →
Treatment with Omega-3 Fatty Acids and Products Thereof
Application:
11/267,581 →
Treating morning migraines with propranolol
Application:
11/239,687 →
Essential Fatty Acids in the Treatment and/or Inhibition of Depression in Patients with Coronary Heart or Artery Disease
Application:
11/106,482 →
Use of Epa and Dha in Secondary Prevention
Application:
10/979,751 →
Pulsatile release histamine H2 antagonist dosage form
Application:
10/875,627 →
Treatment of diabetic patients with omega-3-fatty acids
Application:
10/792,918 →
Pulsatile release histamine H2 antagonist dosage form
Application:
10/689,566 →
Timed Pulsatile Drug Delivery Systems
Application:
10/675,656 →
Timed, sustained release systems for propranolol
Application:
10/453,848 →
Extended Release Dosage Forms of Propranolol Hydrochloride
Application:
10/335,295 →
Pulsatile Release Histamine H2 Antagonist Dosage Form
Application:
10/057,759 →
Timed, Sustained Release Systems for Propranolol
Application:
09/971,167 →
Essential Fatty Acids in the Prevention of Cardiovascular Events
Application:
09/869,333 →
Timed Pulsatile Drug Delivery Systems
Application:
09/778,645 →